IOL Chemicals and Pharmaceuticals Ltd. Reports Unaudited Standalone Earnings Results for the Third Quarter and Nine Months Ended December 31, 2015
January 30, 2016 at 06:38 am EST
Share
IOL Chemicals and Pharmaceuticals Ltd. reported unaudited standalone earnings results for the third quarter and nine months ended December 31, 2015. For the quarter, the company reported net sales/income from operations (net of excise duty) of INR 1,431.471 million against INR 677.949 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 96.275 million against loss from operations before other income, finance costs and exceptional items of INR 180.345 million a year ago. Loss from ordinary activities before tax was INR 57.572 million against INR 320.955 million a year ago. Net loss for the period was INR 62.219 million against INR 300.938 million a year ago. Basic and diluted loss per share was INR 1.14 against INR 7.56 a year ago.
For the nine months, the company reported net sales/income from operations of INR 4,382.332 million against INR 3,098.979 million a year ago. Profit from operations before other income, finance costs and exceptional items was INR 51.813 million against loss from operations before other income, finance costs and exceptional items of INR 1.567 million a year ago. Loss from ordinary activities before tax was INR 401.417 million against INR 445.011 million a year ago. Net loss for the period was INR 411.526 million against INR 385.952 million a year ago. Diluted loss per share was INR 7.99 against INR 9.66 a year ago.
IOL Chemicals and Pharmaceuticals Limited is engaged in manufacturing and selling of pharmaceutical and chemical products. The Company operates through two segments: Chemical, and Pharmaceutical. The Chemical segment produces and sells Ethyl Acetate, Iso Butyl Benzene, Acetyl Chloride, Mono Chloro Acetic Acid, Para Amino Phenol (PAP), and others. The Pharmaceutical segment produces and sells various active pharma ingredients (API) include Ibuprofen, Metformin, Fenofibrate, Lamotrigine, Clopidogrel Bisulphate, Pantoprazole, Gabapentin, Paracetamol, and others. Its API product portfolio includes Ibuprofen, Metformin HCL, Pantoprazole Sodium, Clopidogrel Bisulphate (Form II), Lamotrigine, Losartan Potassium, Levetiracetam, Paracetamol, Fenofibrate (Micronised), and Gabapentin. Its Specialty Chemical division includes Ethyl Acetate, and Acetic Anhydride. Its Ethyl Acetate is used in industries like flexible packaging, pharmaceuticals, ink, food processing, pesticides, and paint industry.